US FDA accepts Samsung Bioepis' Remicade biosimilar for review

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Monoclonal antibodies

The US FDA has accepted Samsung Bioepis’ infliximab biosimilar – known as SB2 - for review.

The US regulator will assess data from Phase I and Phase III clinical studies that compared the drug with Janssen’s reference product Remicade (infliximab).

The Incheon, Korea headquartered firm – a joint venture between conglomerate Samsung and Switzerland’s Biogen – said that, if approved, SB2 will be sold in the US by Merck & Co,  known as MSD outside the US and Canada.

US drug giant Pfizer is expected to launch its own version of Remicade in the US last year.

The Pfizer drug was approved by the FDA in February​ and was the first biosimilar monoclonal antibody (mAb) to be cleared in the US.

Related topics: Markets & Regulations, Cell lines

Related news

Show more

Related products

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us


View more